FOLLOW US

Endocrine Research Updates

For Medical Professionals

Adding locaserin may improve reduce heart disease, obesity and diabetes.
Brief news features on recently released FDA approvals and preliminary clinical trials results for the weight loss drug locaserin, a diabetes combination therapy, and inhaled insulin.
New study supports first effective treatment for cardiomyopathy in diabetes.
Researchers say tafamidis may also slow cognitive functional decline; findings were lauded by an independent expert who called cardiovascular benefits ''substantial."
Non-alcoholic fatty liver disease is strongly associated with hypothyroidism.
A closer look at new data supports a strong association between low thyroid function and liver disease with likelihood of non-alcoholic fatty liver disease tied to degree of hypothyroidism.
Late effect growth hormone deficiency is rising in children treated for cancer.
Seeking better overall care, as the prevalence of cancer survivorship grows in the pediatric population, so may the risk for late effect growth hormone deficiency, particularly among those receiving radiation.
Treatment with specialized antibody preserves pancreatic beta cell function.
Early introduction of a specialized antibody agent may preserve β-cell function to sufficiently improve HbA1c in new-onset type 1 diabetes.
A combination of Dapa and a potent omega 3 agent seem to treat NAFLD.
Combination therapy with SGLT2i and a potent omega-3 formula appears to reduce liver fat content; and dapagliflozin alone may be disease-modifying for NAFLD.
Until now, the only treatment for nonalcoholic fatty liver disease is weight loss but combination therapy with an SGLT2i plus omega 3 holds promise.
People with type 2 diabetes have different risk factors for heart disease.
Inflammation and endothelial stress increase the risk for cardiovascular disease, and the severity of atherosclerosis raises the risk further in patients with no prior history of CVD.
New molecular tests deliver clear cytological analysis of thyroid tumors.
A closer look at the validity and efficacy of four molecular tests, including an expert review and assessment of their recommended use in clinical practice.
New research is bringing the prospect of a diabetes ever closer.
The potential for achieving remission in newly diagnosed diabetes appears feasible given recent evidence that changes that induce beta cell function may induce disease remission for type 1 diabetes and reverse type 2 diabetes.
Patients with polycystic ovary syndrome need earlier screenings and follow-up.
The International PCOS Network cites need for screening for polycystic ovary syndrome in adolescent girls to improve long-term outcomes including diabetes, depression, and cardiovascular disease
Longer use FreeStyle Libre sensor approved; new diabetes drugs on the horizon.
Food and Drug Administration recognized potential for a variety of clinical advances in diabetes care including approval of 14-day use of Freestyle Libre CGM sensor, IND trial of new drug to improve vision in severe diabetic retinopathy, and NDA to market nasal glucagon for hypoglycemia rescue.
Less drastic treatments for most thyroid tumors offer same outcomes as surgery.
Further evidence suggests need for reevaluation of treatment for most thyroid nodules, challenging the preference for total thyroidectomy over lobectomy or active surveillance in thyroid cancer.
Active surveillance should be presented as an objective option over surgery.
A discussion protocol that prompts shared decision making based on objective treatment considerations of asymptomatic, small papillary thyroid tumors makes room for active surveillance over total thyroidectomy.
Lifestyle including diet and body weight are key to preventing diabetes.
Women with a history of gestational diabetes who are poor metabolizers of branched-chain amino acids might develop type 2 diabetes at a greater rate later in life.
Acromegaly requires early and effective treatment to restore quality of life;
When surgery is not pursued as first-line therapy, medication selection is critical to address risk of diabetes, hypertension, and cardiovascular disease to assure best long-term management.
Monitoring patients for signs hypparaothryoidism following thyroid surgery.
American Thyroid Association Statement offers recommendations for clinical management of hypoparathyroidism following thyroid surgery.
FDA grants orphan drug status to thyroid cancer and hypoparathyroidism.
Next generation tubeless Omnipod DASH Insulin Management System coming to market, a novel nasal spray product for diabetes gastoparesis is under review., and orphan drug status granted for treatment of hypoparathyroidism and anaplastic thyroid cancer..
Cushing's syndrome and Cushing's disease requires multimodal care.
Results of two systematic reviews indicate that while surgery is the preferred treatment, many patients present with contraindications without an accepted management paradigm leaving clinicians to follow a patient-centric approach to care.
Several novel diabetes management devices and technolgoy advances are approaching FDA review including first of its kind all-in-one patch, a much anticipated insulin capsule, and a shelf-stable glucagon rescue pen for severe hypoglycemia.
Symptoms of Hashimoto's disease are worsened in women with PCOS.
Hashimoto's disease (autoimmune thyroiditis) worsens reproductive and metabolic outcomes in patients with polycystic ovary syndrome.
SHOW MAIN MENU
SHOW SUB MENU